Chemotherapy-Induced Neuropathy in Cancer Survivors
- PMID: 28063866
- PMCID: PMC5496793
- DOI: 10.1016/j.jpainsymman.2016.12.342
Chemotherapy-Induced Neuropathy in Cancer Survivors
Abstract
Context: Evidence suggests that chemotherapy-induced neuropathy (CIN) is a significant problem for cancer survivors. However, a detailed phenotypic characterization of CIN in cancer survivors is not available.
Objectives: To evaluate between-group differences in demographic and clinical characteristics, as well as in measures of sensation, function, and postural control, in a sample of cancer survivors who received a platinum and/or a taxane-based CTX regimen and did (n = 426) and did not (n = 197) develop CIN.
Methods: Survivors completed self-report questionnaires and underwent objective testing (i.e., light touch, pain sensation, cold sensation, vibration, muscle strength, grip strength, Purdue Pegboard test, Timed Get Up and Go test, Fullerton Advanced Balance test). Parametric and nonparametric statistics were used to compare between-group differences in study outcomes.
Results: Of the 426 survivors with CIN, 4.9% had CIN only in their upper extremities, 27.0% only in their lower extremities, and 68.1% in both their upper and lower extremities. Demographic and clinical characteristics associated with CIN included the following: older age, lower annual income, higher body mass index, a higher level of comorbidity, being born prematurely, receipt of a higher cumulative dose of chemotherapy, and a poorer functional status. Survivors with CIN had worse outcomes for all of the following objective measures: light touch, pain, temperature, vibration, upper and lower extremity function, and balance.
Conclusions: This study is the first to provide a detailed phenotypic characterization of CIN in cancer survivors who received a platinum and/or a taxane compound. These data can serve as a benchmark for future studies of CIN in cancer survivors.
Keywords: Chemotherapy-induced neuropathy; balance; cancer; chemotherapy; gait; pain; pain qualities; sensations; vibration.
Copyright © 2017 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.
Figures



Similar articles
-
Hearing loss and tinnitus in survivors with chemotherapy-induced neuropathy.Eur J Oncol Nurs. 2018 Feb;32:1-11. doi: 10.1016/j.ejon.2017.10.006. Epub 2017 Nov 7. Eur J Oncol Nurs. 2018. PMID: 29353626 Free PMC article.
-
Age-related differences in patient-reported and objective measures of chemotherapy-induced peripheral neuropathy among cancer survivors.Support Care Cancer. 2019 Oct;27(10):3905-3912. doi: 10.1007/s00520-019-04695-3. Epub 2019 Feb 15. Support Care Cancer. 2019. PMID: 30770977 Free PMC article.
-
Associations Between Perceived Stress and Chemotherapy-Induced Peripheral Neuropathy and Otoxicity in Adult Cancer Survivors.J Pain Symptom Manage. 2018 Jul;56(1):88-97. doi: 10.1016/j.jpainsymman.2018.02.021. Epub 2018 Mar 7. J Pain Symptom Manage. 2018. PMID: 29524582 Free PMC article.
-
[Peripheral neuropathy as a side effect of chemotherapy and targeted therapy].Dtsch Med Wochenschr. 2018 Jul;113(13):970-978. doi: 10.1055/s-0043-120839. Epub 2018 Jul 4. Dtsch Med Wochenschr. 2018. PMID: 29972842 Review. German.
-
[Chemotherapy-induced peripheral neuropathy: Symptomatology and epidemiology].Bull Cancer. 2018 Nov;105(11):1020-1032. doi: 10.1016/j.bulcan.2018.07.009. Epub 2018 Sep 20. Bull Cancer. 2018. PMID: 30244980 Review. French.
Cited by
-
Sociodemographic, Clinical, Lifestyle, and Psychological Correlates of Peripheral Neuropathy among 2- to 12-Year Colorectal Cancer Survivors.Oncol Res Treat. 2022;45(9):480-493. doi: 10.1159/000524037. Epub 2022 Mar 18. Oncol Res Treat. 2022. PMID: 35306496 Free PMC article.
-
Characterization of Patients With and Without Painful Peripheral Neuropathy After Receiving Neurotoxic Chemotherapy: Traditional Quantitative Sensory Testing vs C-Fiber and Aδ-Fiber Selective Diode Laser Stimulation.J Pain. 2022 May;23(5):796-809. doi: 10.1016/j.jpain.2021.11.011. Epub 2021 Dec 9. J Pain. 2022. PMID: 34896646 Free PMC article. Clinical Trial.
-
Mechanisms, Predictors, and Challenges in Assessing and Managing Painful Chemotherapy-Induced Peripheral Neuropathy.Semin Oncol Nurs. 2019 Jun;35(3):253-260. doi: 10.1016/j.soncn.2019.04.006. Epub 2019 Apr 30. Semin Oncol Nurs. 2019. PMID: 31053396 Free PMC article. Review.
-
Pain management in cervical cancer.Front Oncol. 2024 Apr 25;14:1371779. doi: 10.3389/fonc.2024.1371779. eCollection 2024. Front Oncol. 2024. PMID: 38725634 Free PMC article. Review.
-
Sex differences in recovery from postoperative sarcopenia during adjuvant CAPOX therapy for colorectal cancer.J Cancer Res Clin Oncol. 2024 Oct 26;150(10):478. doi: 10.1007/s00432-024-06013-9. J Cancer Res Clin Oncol. 2024. PMID: 39460854 Free PMC article.
References
-
- DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64:252–271. - PubMed
-
- Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32:1941–1967. - PubMed
-
- Pachman DR, Barton DL, Swetz KM, et al. Troublesome symptoms in cancer survivors: fatigue, insomnia, neuropathy, and pain. J Clin Oncol. 2012;30:3687–3696. - PubMed
-
- Bennion AE, Molassiotis A. Qualitative research into the symptom experiences of adult cancer patients after treatments: a systematic review and meta-synthesis. Support Care Cancer. 2013;21:9–25. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical